Clinic Directory — coming soon. Are you an Australian peptide clinic?Apply to be listed →
Independent · Australian · Education only — not medical adviceAboutEditorial standardsHow we review
HomeEncyclopediaDulaglutide

Dulaglutide

GLP-1 receptor agonist

Prescription medicine

What it is

A once-weekly GLP-1 receptor agonist used in type 2 diabetes.

What the evidence shows

Supported by large clinical trials for its registered diabetes indications.

Safety & reported risks

Gastrointestinal side effects are common; prescribers screen for contraindications and monitor use.

Status in Australia

A registered prescription medicine in Australia for defined indications, supplied via prescription and pharmacy.

How it’s lawfully accessed

Lawful access is via prescription and pharmacy dispensing of the registered product.

Related peptides

SemaglutideGLP-1 receptor agonistPrescription medicineTirzepatideDual GIP/GLP-1 agonistPrescription medicineExenatideGLP-1 receptor agonistPrescription medicine

Sources & further reading

This entry is general information about Dulaglutide, not a recommendation to use it. We don’t provide dosing, protocols or sourcing. Speak to a registered practitioner.

Written by The Peptides.au editorial team
Editorial review Checked against current TGA, ARTG and AHPRA public guidance
Last updated 1 June 2026

This is general education, not medical advice. Peptides.au does not sell, supply, recommend or promote any product or clinic. Always speak with a registered Australian health practitioner before making any health decision.